There was intensive insider selling in Genco Shipping & Trading (NYSE:GNK) in May 2008 when the stock was trading above $75. The stock is currently trading at $1.35 or 98.3% below the all time high made in 2008.

The stock was not purchased by any insiders in the month of intensive selling.

At least two sellers decreased their holdings by more than 10%.

In this article, I will feature three stocks that met these three criteria of intensive insider selling in the last 30 days.

1. Torchmark Corporation (NYSE:TMK) provides various life and health insurance products, and annuities in the United States, Canada, and New Zealand.

Click to enlarge

Insider selling by insider (last 30 days)

Mark McAndrew sold 156,000 shares on May 14 and currently holds 195,921 shares or 0.2% of the company. Mark McAndrew is Executive Chairman of the Board.

Spencer Stone sold 3,125 shares on May 7 and currently holds 27,099 shares or less than 0.1% of the company. Spencer Stone is Controller of the company.

Roger Smith sold 11,250 shares on May 6 and currently holds 34,532 shares or less than 0.1% of the company. Roger Smith is Chief Executive Officer of American Income Life, a subsidiary of Torchmark Corporation.

Ben Lutek sold 14,000 shares on May 7 and currently holds 12,800 shares or less than 0.1% of the company. Ben Lutek is Vice President and Chief Actuary.

David Carlson sold 2,063 shares on May 3 and currently holds 2,812 options or less than 0.1% of the company. David Carlson is an insider of the company.

Charles Adair sold 9,000 shares on May 2 and currently holds 11,396 shares or less than 0.1% of the company. Charles Adair serves as a director of the company.

Vern Herbel sold 22,500 shares on May 1 and currently holds 39,200 shares or less than 0.1% of the company. Vern Herbel is Executive Vice President and Chief Administrative Officer.

Alan Hintz sold 3,750 shares on April 30 and currently holds 15 shares or less than 0.1% of the company. Alan Hintz is an insider of the company.

Michael Henrie sold 1,219 shares on April 29 and currently holds zero shares of the company. Michael Henrie is an insider of the company.

There have been 639,601 shares sold and zero shares purchased this year.

Financials

The company reported the first-quarter financial results on April 23 with the following highlights:

Net income

$119.6 million

Book value

$45.88 per share

Click to enlarge

Outlook

Torchmark projects that for the year ending December 31, 2013, net operating income per share will range from $5.50 to $5.75.

Competition

Torchmark's competitors include Prudential Financial (NYSE:PRU) and Unum Group (NYSE:UNM). Here is a table comparing these companies.

Company

TMK

PRU

UNM

Industry Average (Life Insurance)

Market Cap:

6.11B

31.60B

7.71B

77.26B

Employees:

2,570

48,498

9,100

64.00K

Qtrly Rev Growth (yoy):

0.06

0.10

0.01

0.14

Revenue:

3.66B

85.75B

10.53B

63.13B

Gross Margin:

0.29

0.13

0.28

0.18

EBITDA:

873.52M

2.10B

1.48B

2.61B

Operating Margin:

0.24

0.02

0.13

0.10

Net Income:

530.22M

684.00M

893.10M

N/A

EPS:

5.52

1.44

3.23

1.39

P/E:

11.81

47.12

8.95

45.19

PEG (5 yr expected):

1.24

0.64

0.91

1.21

P/S:

1.66

0.36

0.73

1.27

Click to enlarge

Click to enlarge

Torchmark is trading above the industry average P/S ratio, which could explain some of the insider selling.

My analysis

There have been nine insider sell transactions and there have not been any insider buy transactions during the last 30 days. The company has an insider ownership of 1.47%. The stock is trading at a P/E ratio of 11.81 and a forward P/E ratio of 10.45. The company has a book value of $45.88 per share and the stock has a dividend yield of 1.05%. Before entering short this stock, I would like to get a bearish confirmation from the Point and Figure chart. The two main reasons for the proposed short entry are relatively high P/S ratio and the intensive insider selling activity.

2. BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world.

Click to enlarge

Insider selling by insider (last 30 days)

Jean Bienaime sold 70,800 shares on April 30 - May 14 and currently holds 157,000 options or 0.1% of the company. Jean Bienaime joined BioMarin in May 2005 as Chief Executive Officer and member of the Board of Directors.

Jeffrey Ajer sold 7,856 shares on April 19 - May 13 pursuant to a Rule 10b5-1 trading plan. Jeffrey Ajer currently holds 7,270 shares or less than 0.1% of the company. Jeffrey Ajer joined BioMarin in 2005 and is currently the Senior Vice President and Chief Commercial Officer.

George Davis sold 28,444 shares on May 3-14 and currently holds 41,708 shares or less than 0.1% of the company. George Davis joined BioMarin in March 2004, and currently serves as Senior Vice President, General Counsel and Secretary.

Robert Baffi sold 40,000 shares on May 3-14 pursuant to a Rule 10b5-1 trading plan. Robert Baffi currently holds 50,262 shares or less than 0.1% of the company. Robert Baffi joined BioMarin in May 2000 and currently serves as Executive Vice President of Technical Operations.

Brian Mueller sold 21,778 shares on May 2-14 and currently holds 6,660 shares or less than 0.1% of the company. Brian Mueller is Vice President, Corporate Controller.

Daniel Spiegelman sold 28,000 shares on May 1 and currently holds 33,000 shares or less than 0.1% of the company. Daniel Spiegelman joined BioMarin in 2012 and is the current Executive Vice President and Chief Financial Officer.

Henry Fuchs sold 20,000 shares on April 30 and currently holds 44,589 shares or less than 0.1% of the company. Henry Fuchs joined BioMarin in 2009 and is the current Executive Vice President and Chief Medical Officer.

Mark Wood sold 3,102 shares on April 22 pursuant to a Rule 10b5-1 trading plan. Mark Wood currently holds 23,245 shares or less than 0.1% of the company. Mark Wood joined BioMarin in May 2004 and currently serves as the Senior Vice President of Human Resources and Corporate Affairs.

The company has a product pipeline, with multiple clinical and preclinical IND (Investigational New Drug) candidates in development.

Click to enlarge

My analysis

There have been 20 insider sell transactions and there have not been any insider buy transactions during the last 30 days. The company has an insider ownership of 0.31% and the company has a book value of $9.00 per share. Before entering short this stock, I would like to get a bearish confirmation from the Point and Figure chart. The two main reasons for the proposed short entry are negative earnings and the intensive insider selling activity.

The company reported the fiscal 2013 second-quarter, which ended April 14, financial results on May 7 with the following highlights:

Revenue

$3.0 billion

Net income

142 million

Cash

$1.1 billion

Debt

$27.0 million

Click to enlarge

Outlook

Based on its year-to-date results and updated assumptions on May 7, the company narrowed its comparable and identical store sales growth ranges for the fiscal year, and raised its EPS range to $2.86 to $2.89. On a 52-week to 52-week basis, the company now expects sales growth of 12% to 14% and diluted earnings per share growth of 15% to 17%.

Competition

Whole Foods Market's competitors include The Kroger Co. (NYSE:KR). Here is a table comparing these two companies.

Company

WFM

KR

Industry Average (Grocery Stores)

Market Cap:

19.14B

18.34B

15.85B

Employees:

74,000

343,000

151.00K

Qtrly Rev Growth (yoy):

0.13

0.13

0.15

Revenue:

12.52B

96.75B

32.84B

Gross Margin:

0.36

0.21

0.24

EBITDA:

1.17B

4.43B

2.26B

Operating Margin:

0.07

0.03

0.04

Net Income:

517.57M

1.48B

N/A

EPS:

2.77

2.77

1.81

P/E:

37.29

12.71

26.72

PEG (5 yr expected):

1.86

1.70

1.82

P/S:

1.53

0.19

0.38

Click to enlarge

Click to enlarge

Whole Foods Market is trading above the industry average P/S ratio, which could explain some of the insider selling.

My analysis

There have been 15 insider sell transactions and there have not been any insider buy transactions during the last 30 days. The company has an insider ownership of 0.91%. The stock is trading at a P/E ratio of 37.29 and a forward P/E ratio of 30.04. The company has a book value of $19.11 per share and the stock has a dividend yield of 0.77%. Before entering short this stock, I would like to get a bearish confirmation from the Point and Figure chart. The two main reasons for the proposed short entry are relatively high P/S ratio and the intensive insider selling activity.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.